Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $438 from $439 and keeps an Equal Weight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Growth Potential with Promising Product Launches and Robust Pipeline
- Vertex Pharmaceuticals price target raised to $575 from $550 at Citi
- Vertex Pharmaceuticals Hold Rating: Key Factors and Challenges in the IgA Nephropathy Market
- Vertex Pharmaceuticals’ Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating
- Morning Movers: CarMax slips following second quarter results